HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1,2- diarachidonoyl- glycero- 3- phosphocholine

RN given refers to (all-Z)-isomer

Also Known As:

1,2-diarachidyl-3-phosphatidylcholine; 1,2-diradyl-3-phosphatidylcholine; DAPC

Networked: 34 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Membrane Lipids: 1591
  - Phospholipids: 11903
    - Glycerophosphates: 118
      - Phosphatidic Acids: 358
        Glycerophospholipids: 689
        Phosphatidylcholines: 2371
        1,2-diarachidonoyl-glycero-3-phosphocholine: 34

Experts

1.	Kim, Hongkyun: 2 articles (09/2011 - 12/2009)
2.	Oh, Hyun J: 2 articles (09/2011 - 12/2009)
3.	Fallon, Justin R: 2 articles (01/2011 - 11/2006)
4.	Kawamori, Ryuzo: 2 articles (06/2010 - 08/2006)
5.	Kim, Young-Seol: 2 articles (06/2010 - 08/2006)
6.	Yamasaki, Yoshimitsu: 2 articles (06/2010 - 08/2006)
7.	Alber, Michael: 1 article (01/2022)
8.	Ardern-Holmes, Simone: 1 article (01/2022)
9.	Berecki, Géza: 1 article (01/2022)
10.	Berkovic, Samuel F: 1 article (01/2022)

Related Diseases

1.	Myotonia Congenita (Thomsen Disease) 01/14/2011 - "Although adipose-derived stem cells had been used for the experimental treatment of Duchenne/Becker disease with promising results, little is known on the expression and function of DAPC in adipose tissue. "
2.	Atherosclerosis 08/22/2006 - "Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)." 06/15/2010 - "The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial."
3.	Musculoskeletal Diseases (Musculoskeletal Disease) 01/01/2020 - "The current study reveals a novel mechanism of VDR-mediated regulation for Dtna, which may be positively explored in treatments aiming to stabilize the DAPC in musculoskeletal diseases."
4.	Type 2 Diabetes Mellitus (MODY) 06/15/2010 - "The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial."
5.	Carotid Artery Diseases 06/15/2010 - "The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial."

Related Drugs and Biologics

1.	Cilostazol (Pletal)
2.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
3.	Phosphodiesterase Inhibitors
4.	Dystrophin-Associated Protein Complex
5.	Dystrophin
6.	Proteins (Proteins, Gene)
7.	Dystroglycans (Dystroglycan)
8.	Membrane Proteins (Integral Membrane Proteins)
9.	Glycoproteins (Glycoprotein)
10.	Histone Deacetylase Inhibitors

Related Therapies and Procedures

1.	Resistance Training